Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 4:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,845 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dexamethasone/Dexamethasone acetate Clear all
Completed Not applicable Interventional

Gene Expression Analysis of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin Based Chemotherapy Regimen

NCT00250029
View directory record Official record
Conditions
Colonic Diseases, Cancer
Interventions
Oxaliplatin
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
4
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Sep 27, 2011 · Synced Oct 1, 2026, 4:31 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

NCT07169851
View directory record Official record
Conditions
Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
Interventions
LY3537021, Placebo, Standard of Care Antiemetic Therapies, Background Chemotherapy
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Greenbrae, California • Irvine, California • Los Alamitos, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 1, 2026, 4:31 PM EDT
Completed Phase 1 Interventional

SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients

NCT02283775
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Isatuximab SAR650984, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
13
States / cities
Scottsdale, Arizona • Duarte, California • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2021 · Synced Oct 1, 2026, 4:31 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma

NCT01615029
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Part 1 (Dose Escalation): Daratumumab, Part 2 (Dose Expansion): Daratumumab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 1, 2026, 4:31 PM EDT
Completed Phase 4 Interventional

The SITE Study - Dexamethasone Ophthalmic Insert In OR on Day of Surgery Versus In-office Post-Op Day 1

NCT05143281
View directory record Official record
Conditions
Cataract
Interventions
Dexamethasone 0.4 MG [Dextenza]
Drug
Lead sponsor
Grene Vision Group
Other
Eligibility
65 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Oct 1, 2026, 4:31 PM EDT
Withdrawn Phase 1 Interventional

Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

NCT03591744
View directory record Official record
Conditions
Plasma Cell Leukemia
Interventions
Bortezomib, Daratumumab, Dexamethasone, Lenalidomide, Pegylated Liposomal Doxorubicin Hydrochloride
Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Duarte, California • Rochester, Minnesota • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 1, 2026, 4:31 PM EDT
Not listed Phase 4 Interventional

Assessing the Efficacy and Safety fo DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert(s) for the Treatment of Pain, Inflammation, and Cystoid Macular Edema Following 27 Gauge Vitrectomy With Internal Limiting Membrane Peel for the Treatment of Retinal Edema Associated With Macular Pucker.

NCT04501367
View directory record Official record
Conditions
Vitrectomy, Macular Pucker, Retinal Edema
Interventions
Dexamethasone Intracanalicular Insert, 0.4 mg, Prednisone acetate 1%
Drug
Lead sponsor
Kovach Eye Institute
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Elmhurst, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 1, 2026, 4:31 PM EDT
Completed Phase 4 Interventional Results available

Ropivacaine Block Alone or With Perineural or Systemic Dexamethasone for Pain in Shoulder Surgery

NCT01450007
View directory record Official record
Conditions
Shoulder Injury
Interventions
Ropivacaine, Dexamethasone, Normal saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 17, 2016 · Synced Oct 1, 2026, 4:31 PM EDT
Completed Phase 2 Interventional

Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma

NCT00003007
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
recombinant interferon alfa, sargramostim, cyclophosphamide, dexamethasone, melphalan, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Tennessee
Other
Eligibility
19 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
4
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 1, 2026, 4:31 PM EDT
Completed Phase 1 Interventional

Intravitreal Carboplatin for the Treatment of Participants With Recurrent or Refractory Intraocular Retinoblastoma

NCT02792036
View directory record Official record
Conditions
Retinoblastoma
Interventions
Carboplatin, Maxitrol®, Focal Therapy, Plaque Radiotherapy
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Oct 1, 2026, 4:31 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide

NCT03151811
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Melflufen, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Oncopeptides AB
Industry
Eligibility
18 Years and older
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
14
States / cities
Tucson, Arizona • Fresno, California • Gainesville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 1, 2026, 4:31 PM EDT
Completed Phase 1 Interventional

A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

NCT01711671
View directory record Official record
Conditions
Multiple Myeloma
Interventions
DKN-01 300 mg, DKN-01 600 mg, Standard of Care
Drug
Lead sponsor
Leap Therapeutics, Inc.
Industry
Eligibility
30 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 1, 2026, 4:31 PM EDT
Recruiting Phase 4 Interventional

Pectoral Block in Breast Reduction for Pain Control

NCT07527039
View directory record Official record
Conditions
Macromastia (Symptomatic)
Interventions
Pectoral II Nerve Block, Post Operative Pain Relievers
Procedure · Drug
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 1, 2026, 4:31 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer

NCT01607554
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Irinotecan
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Albuquerque, New Mexico • Santa Fe, New Mexico
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 1, 2026, 4:31 PM EDT
Withdrawn Phase 4 Interventional

Otiprio Versus Ciprodex Tympanostomy Tube Outcomes

NCT03347461
View directory record Official record
Conditions
Otorrhea, Otitis Media With Effusion in Children
Interventions
Otiprio, Ciprodex
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
6 Months to 10 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 14, 2018 · Synced Oct 1, 2026, 4:31 PM EDT
Terminated Phase 2 Interventional

Randomized Phase II Trial of Doxil With or Without Dexamethasone for Metastatic Hormone Refractory Prostate Cancer

NCT00176293
View directory record Official record
Conditions
Prostate Cancer
Interventions
dexamethasone, doxorubicin
Drug
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 21, 2015 · Synced Oct 1, 2026, 4:31 PM EDT
Completed Phase 2 Interventional Results available

Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma

NCT00282087
View directory record Official record
Conditions
Leiomyosarcoma, Uterine Neoplasm
Interventions
gemcitabine, docetaxel, doxorubicin
Drug
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
18 Years and older · Female only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
12
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Oct 1, 2026, 4:31 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye

NCT00765804
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
EGP-437 with EyeGate® II System, Sodium citrate buffer solution with EyeGate® II System
Drug
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Andover, Massachusetts • North Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2010 · Synced Oct 1, 2026, 4:31 PM EDT
Completed Phase 4 Interventional Results available

Effect of Intraoperative Dexamethasone on Post-op Dry Eye

NCT04184999
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
dexamethasone intraocular suspension, 9%, Prednisolone Acetate 1% Oph Susp
Drug
Lead sponsor
SR Cornea Consultants
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Sycamore, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 1, 2026, 4:31 PM EDT
Completed Phase 2 Interventional Results available

Dexamethasone Treatment of Congenital Adrenal Hyperplasia

NCT00621985
View directory record Official record
Conditions
Adrenal Hyperplasia, Congenital
Interventions
dexamethasone, Hydrocortisone
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 9 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2011 · Synced Oct 1, 2026, 4:31 PM EDT
Completed No phase listed Observational

Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS

NCT00232193
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis, Clinically Isolated Syndrome
Interventions
Not listed
Lead sponsor
Providence Multiple Sclerosis Center
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 22, 2011 · Synced Oct 1, 2026, 4:31 PM EDT
Recruiting Phase 3 Interventional

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

NCT07764978
View directory record Official record
Conditions
Newly Diagnosed Multiple Myeloma
Interventions
AZD0120, Daratumumab, Dexamethasone, Isatuximab, Lenalidomide, Bortezomib, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
45
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 1, 2026, 4:31 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)

NCT00775411
View directory record Official record
Conditions
Choroidal Neovascularization, Age-Related Maculopathy
Interventions
dexamethasone, ranibizumab
Drug · Biological
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 1, 2026, 4:31 PM EDT
Completed Phase 1 Interventional

Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT02095834
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Bendamustine Hydrochloride, Carfilzomib, Dexamethasone, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 1, 2026, 4:31 PM EDT